BioCryst Pharmaceuticals has appointed Dr. David W. Jenkins as Chief Scientific Officer to enhance its research and development efforts, specifically focusing on rare disease therapies. Dr. Jenkins, who has over 20 years of experience in the biopharmaceutical sector, will lead a team dedicated to integrating external innovations and partnerships into the company’s pipeline. His prior role at Ipsen saw the addition of over 35 assets to its portfolio. BioCryst aims to expedite the delivery of treatments for rare diseases, building on successes like the commercialization of ORLADEYO.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.manilatimes.net/2026/07/15/tmt-newswire/globenewswire/biocryst-appoints-david-w-jenkins-as-chief-scientific-officer/2384893
